Bleomycin-induced pulmonary toxitity usually occurs in the elderly patients (graeatee than 70 years old), patients with a cumulative dose above 400 units, previous chest radiotherapy, oxygen therapy, and reanal failure. H owever, there are some reports of severe pneumonitis in that developed after dministering low bleomycin doses (less than 100 units). In sever bleomycin-induced pneumonitis in non-Hodgkin's lymphoma patients, the response to corticosteroid is poor and the mortality rate is very high, approximately 83%. Therefore, clinicians should have a low threshold for investigating and treating bleomycin-induced pneumonitis. Here, we report a case of severe bleomycin-induced pneumonitis as a complication of a non-Hodgkin's lymphoma treatment.
Aged ; Bleomycin ; Humans ; Lymphoma, Non-Hodgkin* ; Mortality ; Oxygen ; Pneumonia* ; Radiotherapy ; Thorax

Chylous effusion is an unusual complication of malignant neoplasm, usually lymphoma. In cases with cancer, the tumor was usually extensive, and the prognosis was invariably poor with a one year mortality rate of 80%. It was also reported that chylous effusion could also result from liver cirrhosis. The incidence of this complication was reported to be 0.5% in patients with liver cirrhosis and ascites. Here we report a case of 62 year old male with chronic alcoholism history who presented with abdom-inal distension and right cervical mass. He was subsequently diagnosed as non-Hodgkin's lymphoma and chylous ascites with liver cirrhosis and treated with chemotherapy. In spite of treatment, lymphoma progressed and the patient expired.
Alcoholism ; Ascites ; Chylous Ascites* ; Drug Therapy ; Humans ; Incidence ; Liver Cirrhosis* ; Liver* ; Lymphoma ; Lymphoma, Non-Hodgkin* ; Male ; Middle Aged ; Mortality ; Prognosis

Primary low-grade lymphoma of the mucosa-associated lymphoid tissue (MALT) type lymphoma of the bladder is rare. A relationship between MALT lymphoma of the urinary bladder and chronic cystitis has been proposed by some reports. Additionally a relationship between MALT lymphoma of the urinary bladder and Helicobacter pylori has been reported. Here we present a case of regression of urinary bladder MALT lymphoma after antibiotic therapy, using H. pylori eradication protocol in an elderly patient, who had a high risk of treatment related mortality in curative systemic chemotherapy. The patient is a 74-year-old woman who had a history of chronic cystitis. She was diagnosed with stage IIA primary MALT lymphoma of the urinary bladder and was treated with H. pylori eradication triple therapy for 2 weeks. After 2 months, there was a marked regression of the bladder MALT lymphoma lesion in a computed tomography scan of the abdomen.
Abdomen ; Aged* ; Cystitis ; Drug Therapy ; Female ; Helicobacter pylori* ; Helicobacter* ; Humans ; Lymphoid Tissue ; Lymphoma ; Lymphoma, B-Cell, Marginal Zone* ; Lymphoma, Non-Hodgkin ; Mortality ; Urinary Bladder*

BACKGROUND: Bendamustine is an attractive option for the management of both de novo and relapsed lymphomas. It is being increasingly used in the conditioning regimen for autologous stem cell transplantation (SCT) and can be an alternative to the traditionally-used carmustine. In this study, we aimed to determine the safety and efficacy of bendamustine in the conditioning regimen for autologous SCT in refractory/relapsed lymphomas. METHODS: We designed a descriptive study to evaluate bendamustine in combination with etoposide, cytarabine, and melphalan (BeEAM) in the conditioning regimen for autologous SCT. RESULTS: Fourteen patients (median age, 28 yr) with Hodgkin's lymphoma (HL) (N=8), non-Hodgkin's lymphomas (NHL) (N=5), or peripheral T-cell lymphoma, not otherwise specified (PTCL NOS) (N=1) were included in the study. A median number of 5.95×10⁶ CD34+ cells/kg were transfused. Median times to absolute neutrophil count and platelet engraftment were 17 days and 24 days, respectively. The 100-day transplantation mortality rate was 28% (4 patients). Eight patients (57.14%) had GII-III acute kidney injury, four patients (28.5%) had GIII-IV hyperbilirubinemia, and twelve patients (85%) had GII-III diarrhea. After 3 months, 37% (5 patients) and 21.4% (3 patients) demonstrated complete response and partial response, respectively. The median follow-up was 5.5 months (15 days–19 mo). At the final follow-up, 7 patients (50%) were alive and in CR. CONCLUSION: Our study showed that bendamustine is a potentially toxic agent in the conditioning regimen for autologous SCT, resulting in significant liver, kidney, and gastrointestinal toxicity. Further studies are required to assess its safety and efficacy at reduced doses.
Acute Kidney Injury ; Bendamustine Hydrochloride ; Blood Platelets ; Carmustine ; Cytarabine ; Diarrhea ; Etoposide ; Follow-Up Studies ; Hodgkin Disease ; Humans ; Hyperbilirubinemia ; Kidney ; Liver ; Lymphoma ; Lymphoma, Non-Hodgkin ; Lymphoma, T-Cell, Peripheral ; Melphalan ; Mortality ; Neutrophils ; Stem Cell Transplantation ; Stem Cells

PURPOSE: This retrospective study was conducted for comparison of survival outcomes and toxicities of autologous stem cell transplantation (ASCT) based on the use of total body irradiation (TBI) as a part of the conditioning regimen in patients with mature T- and natural killer (NK)-cell lymphomas. MATERIALS AND METHODS: Patients who underwent ASCT in the upfront or salvage setting between January 2000 and December 2013 were analyzed. Patients were dichotomized according to the TBI group (n=38) and non-TBI group (n=60) based on the type of conditioning regimen for ASCT. RESULTS: Patients with responsive disease underwent upfront ASCT (TBI, n=16; non-TBI, n=29) whereas patients with refractory disease (TBI, n=9; non-TBI, n=12) or relapsed disease (TBI, n=13; non-TBI, n=19) underwent ASCT after salvage treatment. Hematologic and non-hematologic toxicities were manageable, and the median cumulative toxicity score according to Seattle criteria was estimated as 2 (range, 0 to 7) in both groups. No significant difference in 100-day mortality was observed between the TBI (13%, 5/38) and non-TBI (12%, 12/60) groups, and most deaths were related to disease progression. There was no difference in overall and progression-free survival; however, the TBI group showed a trend of better survival in upfront and salvage ASCT than the non-TBI group. However, patients with refractory disease showed the worst outcome regardless of the use of TBI. Patients who showed complete response before ASCT showed better progression-free survival than thosewho showed partial response. CONCLUSION: TBI could be used as an effective part of conditioning for ASCT in patients with mature T- and NK-cell lymphomas.
Disease Progression ; Disease-Free Survival ; Humans ; Lymphoma ; Lymphoma, Non-Hodgkin* ; Mortality ; Retrospective Studies ; Salvage Therapy ; Stem Cell Transplantation* ; Stem Cells* ; T-Lymphocytes ; Whole-Body Irradiation*

OBJECTIVETo evaluate the clinical characteristics, results of treatment, and prognostic factors of patients diagnosed as having primary female genital system lymphoma (PFGSL).

METHODSTwenty-eight cases of PFGSL were retrospectively surveyed and the clinical data of the patients were analyzed by statistic software package of SPSS10.0 for relation between clinical stage, grade, pathologic feature, treatment and prognosis.

RESULTSThe median age was 44 in the cohort. It mainly involved cervix uterus, ovary and vulva. The disease had a broad range of pathologic type and 20 patients were diagnosed as suffering from B-cell by immunophenotyping, 4 patients were diagnosed as T-cell and 4 patients lesions were indefinite. According to International Working Formulation (IWF), 66.7% belonged to the intermediate-grade. The Ann Arbor stage included: Stage I(E)-12 pts (42.86%), Stage II(E)-3 pts (10.7%), Stage III(E)-1 pts (3.6%) and Stage IV-12 pts (42.86%). According to International Prognostic Index (IPI), 10 were low risk, 9 low-medium risk, 3 medium-high risk and 6 high risk, The median follow-up of the surviving patients was 2.0 years (range: 3 months-17 years), The 5-year overall survival rate was 39.3%. Most patients were given comprehensive treatment without any mode showing significant advantage over the others in survival (P = 0.2554), The involved organs, Ann Arbor stage, IWF and also IPI were significant prognostic factors for survival,

CONCLUSIONThe management of PFGSL should be based on comprehensive treatment including chemotherapy as the chief means. The significant prognostic factors of survival is Ann Arbor stage, IPI, IWF and the kind of involved organs.

Adolescent ; Adult ; Aged ; Child ; Female ; Genital Neoplasms, Female ; mortality ; pathology ; therapy ; Humans ; Lymphoma, Non-Hodgkin ; mortality ; pathology ; therapy ; Middle Aged ; Retrospective Studies ; Survival Rate

p27kip1 is a cyclin-dependent kinase inhibitor that regulates progression from G1 into S phase. Aberrations in cell cycle control are often observed in tumors d might even be necessary in tumor development. Recent reports showed that low 7kip1 expression is associated with poor prognosis in several tumors and ukemia. To investigate the expression of p27kip1 in malignant lymphomas and ucidate the role of p27kip1 as a possible prognostic indicator, the authors rformed an immunohistochemical staining of p27kip1 correlated with Ki-67 belling index and clinical parameters. p27kip1 expression was reduced variably most malignant lymphomas and inversely correlated with Ki-67 labelling index +AD0-0.0151). Regarding chemotherapeutic response, p271kip1 expression in the mplete remission group showed statistically significant difference in pression compared to the progressive disease group (p+AD0-0.0021). There were gnificant differences in survival between cases with low and high p27kip1 pression (p+AD0-0.0071). In a multivariate Cox analysis, p27kip1 expression was dependent prognostic factors as well as other known prognostic factors cluding age, grade, stage and chemotherapeutic response. In conclusion, the udy suggests that reduced expression of p27kip1 protein may play a role in the thogenesis and biologically aggressive behavior of malignant lymphomas.
Adolescence ; Adult ; Aged ; Antineoplastic Agents, Combined/therapeutic use ; Cell Cycle ; Cell Division ; Child ; Child, Preschool ; Comparative Study ; Female ; Follow-Up Studies ; Human ; Ki-67 Antigen/analysis ; Life Tables ; Lymphoma, Non-Hodgkin/pathology ; Lymphoma, Non-Hodgkin/mortality ; Lymphoma, Non-Hodgkin/drug therapy ; Lymphoma, Non-Hodgkin/chemistry+ACo- ; Male ; Microtubule-Associated Proteins/physiology ; Microtubule-Associated Proteins/analysis+ACo- ; Middle Age ; Neoplasm Proteins/physiology ; Neoplasm Proteins/analysis+ACo- ; Prognosis ; Proportional Hazards Models ; Survival Analysis ; Treatment Outcome

p27kip1 is a cyclin-dependent kinase inhibitor that regulates progression from G1 into S phase. Aberrations in cell cycle control are often observed in tumors d might even be necessary in tumor development. Recent reports showed that low 7kip1 expression is associated with poor prognosis in several tumors and ukemia. To investigate the expression of p27kip1 in malignant lymphomas and ucidate the role of p27kip1 as a possible prognostic indicator, the authors rformed an immunohistochemical staining of p27kip1 correlated with Ki-67 belling index and clinical parameters. p27kip1 expression was reduced variably most malignant lymphomas and inversely correlated with Ki-67 labelling index +AD0-0.0151). Regarding chemotherapeutic response, p271kip1 expression in the mplete remission group showed statistically significant difference in pression compared to the progressive disease group (p+AD0-0.0021). There were gnificant differences in survival between cases with low and high p27kip1 pression (p+AD0-0.0071). In a multivariate Cox analysis, p27kip1 expression was dependent prognostic factors as well as other known prognostic factors cluding age, grade, stage and chemotherapeutic response. In conclusion, the udy suggests that reduced expression of p27kip1 protein may play a role in the thogenesis and biologically aggressive behavior of malignant lymphomas.
Adolescence ; Adult ; Aged ; Antineoplastic Agents, Combined/therapeutic use ; Cell Cycle ; Cell Division ; Child ; Child, Preschool ; Comparative Study ; Female ; Follow-Up Studies ; Human ; Ki-67 Antigen/analysis ; Life Tables ; Lymphoma, Non-Hodgkin/pathology ; Lymphoma, Non-Hodgkin/mortality ; Lymphoma, Non-Hodgkin/drug therapy ; Lymphoma, Non-Hodgkin/chemistry+ACo- ; Male ; Microtubule-Associated Proteins/physiology ; Microtubule-Associated Proteins/analysis+ACo- ; Middle Age ; Neoplasm Proteins/physiology ; Neoplasm Proteins/analysis+ACo- ; Prognosis ; Proportional Hazards Models ; Survival Analysis ; Treatment Outcome

PURPOSE: Children with Malignant lymphoma who is in the advanced stage at diagnosis or relapses during treatment have a poor prognosis. Recently, hematopoietic stem cell transplantation (HSCT) for advanced stage or refractory/relapsed lymphoma performed frequently. However, the role for HSCT for children with malignant lymphoma is still controversial. In this study, we reviewed children with malignant lymphoma who received HSCT and analyzed the results. METHODS: Questionnaires were made and sent to a group of teaching hospitals, with a return of 37 questionnaires from 11 hospitals. 33 patients with Non-Hodgkin lymphoma (NHL) and 4 patients with Hodgkin disease (HD) who received HSCT from 1997 to 2004 in Korea were enrolled in this study. Disease state at diagnosis, relapses during treatment, disease state at HSCT, and survival record were analyzed. All Data were reviewed with the questionnaires from the 11 teaching hospitals. RESULTS: Four patients with HD received HSCT at the 2nd complete remission after relapse. Survival rate for HD was 100% and their follow up duration ranged from 0.2 to 6.2 years (median 2.4 years). The 2-year survival rate for NHL was 68.1+/-9.0% and their follow up duration ranged from 0.1 to 7.6 years (median 1.5 years). The 2-year survival rate in patients with advanced stage at diagnosis and in relapsed/refractory patients were 83.6+/-1.1% and 55.9+/-12.9%, respectively (P=0.12). The mortality asssociated with HSCT was only 1 case, and most of the transplantation related complications did not resulted in death. CONCLUSION: Our results suggest that high dose chemotherapy followed by HSCT in children with malignant lymphoma is a safe procedure, which at the same time improves the results of standard treatment.
Child ; Diagnosis ; Drug Therapy ; Follow-Up Studies ; Hematopoietic Stem Cell Transplantation* ; Hematopoietic Stem Cells* ; Hodgkin Disease ; Hospitals, Teaching ; Humans ; Korea* ; Lymphoma* ; Lymphoma, Non-Hodgkin ; Mortality ; Prognosis ; Surveys and Questionnaires ; Recurrence ; Retrospective Studies* ; Stem Cell Transplantation ; Survival Rate

OBJECTIVETo explore the feasible age limits in Chinese elderly patients with non-Hodgkin's lymphoma (NHL).

METHODSThe clinical data of 507 patients with NHL who were admitted to Peking Union Medical College Hospital (PUMCH) from January 1990 to December 2007 were retrospectively analyzed. They were further followed up by reviewing medical records or by phone. The deadline of follow-up was October 2008.

RESULTSThe 5-year/8-year overall survival (OS) rates were 64.6%/45.7%, 53.0%/ 44.1%, 32.8%/17.5%, 40.0%/22.8%, and 19.8%/0, respectively, in patients aged < 60 years, 60-64 years, 65-69 years, 70-74 years, and > or = 75 years. The OS rate was significantly different between patients aged > or = 75 years and other age groups, and between patients aged 65-70 years and patients younger than 60 years (P < 0.05). Only age, serum albumin, and hemoglobin affected the survival status in elderly NHL patients.

CONCLUSIONSixty-five years can be regarded as the age limit in Chinese NHL patients.

Age Factors ; Aged ; Aged, 80 and over ; China ; epidemiology ; Female ; Follow-Up Studies ; Humans ; Lymphoma, Non-Hodgkin ; mortality ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Survival Rate